Literature DB >> 2579970

Immune function in chronic active Epstein-Barr virus infection.

R Kibler, D O Lucas, M J Hicks, B T Poulos, J F Jones.   

Abstract

The spectrum of illness attributed to Epstein-Barr virus (EBV) includes patients with symptoms persisting for more than 1 year without any other obvious underlying disease. High titers of antibodies to EBV, either IgG antiviral capsid antigen or anti-early antigen, can be demonstrated. In this study, 13 patients diagnosed as having chronic active EBV infection were examined to determine aspects of their immunologic status. Morphological examination and fluorescent antibody analysis revealed no abnormalities in the phenotypes of peripheral blood white cells present in these patients. Compared to those from healthy control individuals, mononuclear cells from the patients showed a markedly depressed ability to produce both interleukin-2 and interferon after stimulation with mitogen and a phorbol ester. Studies of natural killer (NK) cell activity revealed that unfractionated mononuclear cells from patients with chronic active EBV infection were significantly lower in killing activity compared to the control group. Fractionation procedures to enrich for large granular lymphocytes resulted in an increase in NK activity for all individuals, but killing activity still remained slightly lower in the patients than in the control group. The dysfunctions which were found in patients with chronic active EBV infection may reflect a primary defect in natural immune functions of the patients predisposing them to a chronic or intermittent clinical disease rather than a self-limiting illness. Alternatively, the abnormalities detected in these experiments may be a result of the viral infection itself.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579970     DOI: 10.1007/bf00915168

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  27 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

3.  Suppressor cells of the human NK activity: characterization of the cells and mechanism of action.

Authors:  J Tarkkanen; E Saksela; E von Willebrand; E Lehtonen
Journal:  Cell Immunol       Date:  1983-07-15       Impact factor: 4.868

4.  Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes.

Authors:  M P Langford; G J Stanton; H M Johnson
Journal:  Infect Immun       Date:  1978-10       Impact factor: 3.441

5.  Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation.

Authors:  R T Schooley; M S Hirsch; R B Colvin; A B Cosimi; N E Tolkoff-Rubin; R T McCluskey; R C Burton; P S Russell; J T Herrin; F L Delmonico; J V Giorgi; W Henle; R H Rubin
Journal:  N Engl J Med       Date:  1983-02-10       Impact factor: 91.245

6.  The transformation of adult but not newborn human lymphocytes by Epstein Barr virus and phytohemagglutinin is inhibited by interferon: the early suppression by T cells of Epstein Barr infection is mediated by interferon.

Authors:  D A Thorley-Lawson
Journal:  J Immunol       Date:  1981-03       Impact factor: 5.422

7.  Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis.

Authors:  E Svedmyr; I Ernberg; J Seeley; O Weiland; G Masucci; K Tsukuda; R Szigeti; M G Masucci; H Blomogren; W Berthold
Journal:  Clin Immunol Immunopathol       Date:  1984-03

8.  Evidence for suppressor T-cell regulation of human gamma interferon production.

Authors:  V Papermaster; B A Torres; H M Johnson
Journal:  Cell Immunol       Date:  1983-07-15       Impact factor: 4.868

9.  Epstein-Barr-virus-induced lymphoproliferative disorder converting to fatal Burkitt-like lymphoma in a boy with interferon-inducible chromosomal defect.

Authors:  K Thestrup-Pedersen; V Esmann; S Bisballe; J R Jensen; G Pallesen; J Hastrup; M Madsen; K Thorling; M Grazia-Masucci; A K Saemundsen; I Ernberg
Journal:  Lancet       Date:  1980-11-08       Impact factor: 79.321

10.  X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency.

Authors:  J L Sullivan; K S Byron; F E Brewster; S M Baker; H D Ochs
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

View more
  14 in total

1.  Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection.

Authors:  M Yanagisawa; M Kato; K Ikeno; T Kobayashi; Y Miyagawa; A Komiyama; T Akabane
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

2.  Immunologic abnormalities in chronic fatigue syndrome.

Authors:  N G Klimas; F R Salvato; R Morgan; M A Fletcher
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

3.  Chronic Epstein-Barr virus syndrome.

Authors:  J F Jones
Journal:  Bull N Y Acad Med       Date:  1988 Jul-Aug

4.  Retroviral sequences related to human T-lymphotropic virus type II in patients with chronic fatigue immune dysfunction syndrome.

Authors:  E DeFreitas; B Hilliard; P R Cheney; D S Bell; E Kiggundu; D Sankey; Z Wroblewska; M Palladino; J P Woodward; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

5.  Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome.

Authors:  J G Cannon; J B Angel; L W Abad; E Vannier; M D Mileno; L Fagioli; S M Wolff; A L Komaroff
Journal:  J Clin Immunol       Date:  1997-05       Impact factor: 8.317

Review 6.  [Chronic fatigue syndrome].

Authors:  S Ewig; H J Dengler
Journal:  Klin Wochenschr       Date:  1990-08-17

7.  Natural killer cell activity during measles.

Authors:  D E Griffin; B J Ward; E Jauregui; R T Johnson; A Vaisberg
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

8.  Lymphocyte phenotype and function in the chronic fatigue syndrome.

Authors:  S E Straus; S Fritz; J K Dale; B Gould; W Strober
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

9.  Psychological and immunological correlates of acute overtraining.

Authors:  R W Fry; J R Grove; A R Morton; P M Zeroni; S Gaudieri; D Keast
Journal:  Br J Sports Med       Date:  1994-12       Impact factor: 13.800

10.  Adrenocortical insufficiency associated with Epstein-Barr virus infection in a patient with the Wiskott-Aldrich syndrome.

Authors:  N T Hertel; B B Jacobsen; F K Pedersen; C Heilmann
Journal:  Eur J Pediatr       Date:  1987-11       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.